Deregulation of FoxO3a accelerates prostate cancer progression in TRAMP mice

• Published in: The Prostate Vol. 73; no. 14; pp. 1507 - 1517
• Main Authors: Shukla, Sanjeev, Bhaskaran, Natarajan, MacLennan, Gregory T., Gupta, Sanjay
• Format: Journal Article
• Language: English
• Published: United States Blackwell Publishing Ltd 01.10.2013; Wiley Subscription Services, Inc
• Subjects: Adenocarcinoma - genetics; Adenocarcinoma - pathology; Animals; cell cycle; Cell Proliferation; Disease Models, Animal; Disease Progression; Forkhead Box Protein O3; forkhead transcription factors; Forkhead Transcription Factors - genetics; Forkhead Transcription Factors - metabolism; Humans; Immunohistochemistry; Male; Mice; Mice, Transgenic; Phosphatidylinositol 3-Kinases - genetics; Phosphatidylinositol 3-Kinases - metabolism; PI3K/Akt; prostate cancer; Prostatic Neoplasms - genetics; Prostatic Neoplasms - pathology; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt - genetics; Proto-Oncogene Proteins c-akt - metabolism; PTEN; Signal Transduction; TRAMP; Transcription Factors - genetics; Transcription Factors - metabolism; Transcriptional Activation; PTEN; forkhead transcription factors; prostate cancer; TRAMP; cell cycle; PI3K/Akt
• ISSN: 0270-4137; 1097-0045
• DOI: 10.1002/pros.22698

BACKGROUND Forkhead box, class “O” (FoxO) transcription factors are involved in multiple signaling pathways and possess tumor suppressor functions. Loss of PTEN and activation of PI3K/Akt is frequently observed in prostate cancer, which may potentially inactivate FoxO activity. We therefore investigated the role of FoxO transcription factors in prostate cancer progression, in particular FoxO3a, in transgenic adenocarcinoma of the mouse prostate (TRAMP) mice, which mimics progressive forms of human disease. METHODS Prostate cancer progression in TRAMP mice was followed from 8 to 28 weeks. Expression patterns of Akt, FoxO1a, FoxO3a, FoxO4, and their phosphorylated form, DNA binding activity and downstream signaling molecules during different stages of disease progression were examined by immunoblotting, immunoprecipitation, enzyme‐linked immunoabsorbant assay (ELISA), and immunohistochemistry. Inhibition of FoxO3a activity was attained by using FoxO3a peptide treatment to TRAMP mice. RESULTS In TRAMP mice, FoxO3a activity is negatively regulated by Akt/PKB through post‐translational modification. Progressive increase in Akt activation during prostate cancer progression led to increase phosphorylation of FoxO3a and binding with 14‐3‐3, which potentially affected its transcriptional activity in age‐specific manner. Furthermore, blocking FoxO3a activity resulted in accelerated prostate cancer progression in these mice, which was associated with the loss of cell cycle control and increased proliferation and survival markers. CONCLUSIONS Restoration of FoxO3a activity represents an attractive therapeutic target in the chemoprevention and possibly in inhibition of progression of prostate cancer. Prostate 73: 1507–1517, 2013. © 2013 Wiley Periodicals, Inc.